The FDA has accepted Biogen Idec's biologics license application for hemophilia A drug candidate eloctate. The recombinant factor VIII Fc fusion protein are intended to permit longer intervals between factor VIII treatments.
FDA to review Biogen's hemophilia A treatment eloctate
SmartBrief Job Listings for Health Care
|Vice President of Regulatory Affairs||
|Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX||
|Santa Clara, CA|
|Senior Director, Biostatistics||